Sanemus

The firm website lists three active portfolio companies. ProPharm AG is a cooperative network of 75 independent German pharmacies that bundles purchasing, marketing, and mail-order services. Aureleon Diagnostics GmbH is developing multiplex diagnostic tests for cardiac and oncology applications. 52masterworks GmbH runs a crowd-investing marketplace for contemporary fine art.

Michael Thiess leads the investment process in his role as partner and board member. Sonja Hager, a Certified Private Equity Analyst, joined the management board in December 2023 and supports decision-making as the senior investment professional. The three-member supervisory board offers additional governance.

No. The company identifies as a private equity firm but does not raise funds from external limited partners. It invests its own balance-sheet capital alongside its advisory business, which generates outside fee revenue from strategic and M&A consulting, blurring the line between a fund manager and a corporate-finance boutique.

Altss research tags the firm as active across early-stage start-up, expansion, and growth phases. The portfolio reflects this range: ProPharm was a late-stage service-platform investment, while aureleon diagnostics represents a clinical-stage life-science play.

The firm explicitly names pharmaceuticals, biotechnology, medical technology, diagnostics, and e-health. Its pharmaceutical investments center on distribution and margin improvement rather than drug discovery, while the diagnostics exposure targets algorithmic multiplex biomarker analysis.

Both sit inside Sanemus AG. The firm publicly states it offers strategic, financial, and M&A advisory to third parties while managing its own direct investments. Fee income from advisory mandates replenishes the investment pool organically, which means the firm can deploy capital without marketing to external LPs.